tradmap

TVGN Financials Tevogen Bio Holdings Inc.

4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Financial health

  • The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
-$60M -$28M $4M $0 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2022 2023 2024 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$12M -$6M $0 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $3M $5M 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$12M -$49625 $12M $0 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$26M -$12M $552372
2024 -$14M $1M
2023 -$60M -$8M $1M
2022 $4M $5M

Frequently asked questions

Is TVGN growing its revenue and profit?

See the revenue and net-income charts above for Tevogen Bio Holdings Inc.'s multi-year trend.

How much debt does TVGN have?

As of FY2025, Tevogen Bio Holdings Inc. reported — of total debt against $552372 of cash.

What is TVGN's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.